Augtyro is the only FDA-approved treatment option for NTRK-positive tumors studied in both TKI-naïve and TKI-pretreated patients across solid tumors
The state-of-the-art facility is equipped with best-in-class equipment and control systems
95.7% of patients responded to Breyanzi in the TRANSCEND FL trial
Subcutaneous nivolumab has potential to be the first and only subcutaneously administered PD-1 inhibitor
Before joining Gland, Loomba was associated with Shalina Labs, Harman Finochem, Aurobindo Pharma, Sun Pharmaceuticals and Ranabaxy Laboratories.
ALPHA Phase III trial showed first-in-class, oral, Factor D inhibitor as add-on to Ultomiris or Soliris improved haemoglobin levels and reduced anaemia and fatigue
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva
Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial
This is the fourth authorized indication in Europe for Reblozyl, a first-in-class treatment for patients with disease-related anemia
This acquisition enables MTD to open new, strategic markets
Subscribe To Our Newsletter & Stay Updated
